AI-powered search

Approaching the Conversation

Featuring Mark Lebwohl, MD | Senior Clinical Advisor |

Dean for Clinical Therapeutics
Waldman Professor
Chairman Emeritus
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

| Published November 01, 2023

Join Mark Lebwohl, MD, as he provides an introduction and overview of the SILIQ® (brodalumab) injection Risk Evaluation and Mitigation Strategy (REMS) Program for patients undergoing treatment for moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.

Dr. Lebwohl discusses the background and rationale of the SILIQ REMS Program, the program requirements, and how he counsels his patients on utilizing the program to ensure their well-being.

See the Full Prescribing Information for SILIQ, including BOXED WARNING about suicidal ideation and behavior, here.


Related Media

Powered by Polaris TM

The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us


Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved